GEO DataSets

Analysis of whole blood from Huntington’s disease (HD) patients and age- and sex-matched healthy controls. To date, a robust and clinically useful blood test for HD has not been developed. Results provide insight into blood biomarkers for HD activity.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 12 age, 2 disease state, 2 gender, 14 individual sets

Platform:

GPL96

Series:

GSE24250

14 Samples

Download data: CEL

(Submitter supplied) To accelerate the development of disease-modifying therapeutics for Huntington’s disease (HD), a dynamic biomarker of disease activity and treatment response is critically needed.

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4541

Platform:

GPL96

14 Samples

Download data: CEL

(Submitter supplied) Transcriptional dysregulation plays a major role in the pathology of Huntington's disease (HD). However, the mechanisms causing selective downregulation of genes remain unknown. Histones regulate chromatin structure and thereby control gene expression; recent studies have demonstrated a therapeutic role for histone deacetylase (HDAC) inhibitors in polyglutamine diseases. This study demonstrates that despite no change in overall acetylated histone levels, histone H3 is hypo-acetylated at promoters of downregulated genes in R6/2 mice, ST14a and STHdh cells, as demonstrated by in vivo chromatin immunoprecipitation. more...

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL1261

8 Samples

Download data: CEL, CHP

(Submitter supplied) Increasing evidence has demonstrated that epigenetic factors can profoundly influence gene expression and, in turn, influence resistance or susceptibility to disease. Epigenetic drugs, such as histone deacetylase (HDAC) inhibitors, are finding their way into clinical practice, although their exact mechanisms of action are unclear. To identify mechanisms associated with HDAC inhibition, we performed microarray analysis on brain and muscle samples treated with the HDAC1/3-targeting inhibitor, HDACi 4b. more...

Organism:

Homo sapiens

Type:

Methylation profiling by genome tiling array

Platform:

GPL13534

12 Samples

Download data: IDAT, TXT

(Submitter supplied) To assess the effects of histone deacetylase (HDAC) inhibitor, HDACi 4b, treatment on muscle function on a molecular level, we performed microarray analysis on skeletal muscle (gastrocnemius) samples from wt and N17182Q mice treated with the HDAC inhibitor 4b for 3 months (50 mg/kg; s.c. injection 3x weekly; n=4 per group). The transcriptome pattern in N17182Q mice compared to wt controls consisted of deficits in the expression of genes related to mitochondrial function and oxidative metabolism. more...

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL6885

16 Samples

Download data: TXT

(Submitter supplied) Codelink Human Uniset I, II, and 20K expression levels for 12 symptomatic and 5 presymptomatic Huntington's disease patients versus 14 healthy controls. Keywords: other

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS1332

Platform:

GPL1449

31 Samples

Download data

(Submitter supplied) Affymetrix U133A expression levels for 12 symptomatic and 5 presymptomatic Huntington's disease patients versus 14 healthy controls. Keywords: other

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS1331

Platform:

GPL96

31 Samples

Download data

Analysis of blood samples of 5 presymptomatic and 12 symptomatic Huntington's disease (HD) patients. Studies suggest that gene expression may be altered in a variety of tissues in HD, including peripheral blood. Results identify potential markers for HD.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 3 disease state sets

Platform:

GPL1449

Series:

GSE1767

31 Samples

Download data

Analysis of blood samples of 5 presymptomatic and 12 symptomatic Huntington's disease (HD) patients. Studies suggest that gene expression may be altered in a variety of tissues in HD, including peripheral blood. Results identify potential markers for HD.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 3 disease state sets

Platform:

GPL96

Series:

GSE1751

31 Samples

Download data

(Submitter supplied) Transcriptional dysregulation has emerged as a core pathologic feature of Huntington's disease (HD), one of several triplet-repeat disorders characterized by movement deficits and cognitive dysfunction. Although the mechanisms contributing to the gene expression deficits remain unknown, therapeutic strategies have aimed to improve transcriptional output via modulation of chromatin structure. Recent studies have demonstrated therapeutic effects of commercially available histone deacetylase (HDAC) inhibitors in several HD models; however, the therapeutic value of these compounds is limited by their toxic effects. more...

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL6103

47 Samples

Download data: CSV

(Submitter supplied) Transcriptional profiles in the HdhQ150 mouse model of HD and wild-type litter mates at 6, 12 and 18 months

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL6246

29 Samples

Download data: CEL, CHP

(Submitter supplied) Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder resulting from expansion in the number of CAG repeats in the coding region of exon 1 of the Huntingtin (HTT) gene. One of the most widely studied chromatin modifications is trimethylated lysine 4 of histone 3 (H3K4me3). Here, we conducted the first comprehensive study of H3K4me3 ChIP-sequencing in neuronal chromatin from the prefrontal cortex of six HD cases and six non-neurologic controls. more...

Organism:

Homo sapiens

Type:

Genome binding/occupancy profiling by high throughput sequencing

Platform:

GPL9115

13 Samples

Download data: TXT